Key Takeaways
- Steady quarter with margin expansion: Revenue grew 2.4% QoQ to INR 784 crores while EBITDA expanded 90 bps to 17%, driven by utilization gains and US profit improvement, despite furlough headwinds.
- Order book and pipeline confidence: The 12-month backlog has grown consistently quarter-on-quarter, and management expressed confidence in the pipeline even while acknowledging client decision delays and macro uncertainty.
- US business crosses a threshold: The US crossed a USD 100 million run rate, giving management confidence to aim for the next USD 100 million, with margins expected to improve as the integrated business scales.
- Strategic exits and account quality shift: The company exited Malaysia, Singapore, and India businesses while sharpening its new-logo focus to clients above USD 1 billion, a deliberate trade-off that caused a temporary attrition spike.
- What to watch next quarter: Whether the NHS revival plan translates into growth in FY '25, the pace of US and Middle East margin improvement toward the 17-19% target range, and stabilization of attrition from geographic exits.
Revenue & Margin Performance
- Topline growth despite furloughs: Revenue of INR 784 crores grew 2.4% QoQ and 19.1% YoY, absorbing furlough impact across geographies.
- Utilization-led margin expansion: EBITDA improved to 17%, up 90 bps QoQ, led by operating levers including a 130 bps improvement in utilization to 85.4% and favorable grade mix.
- US profit inflection: US profit moved up significantly, supporting the overall EBITDA print, as the business crossed a USD 100 million run rate and the new US leader integrated multiple entities into one Mastek.
- BizAnalytica integration complete: The acquisition contributed a full quarter of revenue at USD 4.3 million, with margins now very close to the company average after team-led improvement.
- Headcount reduction: Net headcount declined by 80 to 5,518 as the company continued to improve utilization; management expects to increase headcount in coming quarters as more customers are added.
- No one-off in margins: PPA amortization and unwinding of interest from acquisitions sit below EBITDA, not in business profit, so the 17% margin is clean.
Hiral Chandrana: "some of that might come at margins which are below in the short term. But as long as we are confident that we can drive operational rigor, efficiencies, automation, and making sure that overall profitability is kept at company level, we will go after some of those large deals."
UK Public Sector & Secure Government
- Resilient core with expanding footprint: The UK public sector business continues to be very resilient, expanding within existing departments (immigration, asylums, biometrics) and into newer policy areas including agriculture, food, rural affairs, and the Department of Justice.
- Cabinet Office large deal progressing: The large deal win at the Cabinet Office, announced last quarter, has delivered its first milestone and work continues to expand; the One Login program cuts across the entire UK government.
- New department campaigns underway: The company is running campaigns on new departments aligned to specific policy areas, with civil servants from those departments willing to join Mastek and making a big difference.
- No extended furlough risk: Management does not see a risk of extended furloughs in UK government, and secure government (central government and defense) is expected to continue growing in Q4 and beyond into FY '25.
- Immigration replication potential: Immigration is a big problem globally including Europe and the US; Mastek is looking at potential replication of its UK immigration expertise.
US Business & Healthcare Momentum
- Scale threshold crossed: The US business crossed a USD 100 million run rate, a threshold that gives management confidence to aim for the next USD 100 million, with the new US leader integrating multiple entities into a single, more rigorous operation.
- Margin trajectory improving: US margins, historically lower due to subscale operations and a mix of organic and inorganic entities, are now improving through operating levers, a rigorous qualification process that exits low-margin accounts, and the integrated business model.
- Healthcare momentum strong: Healthcare momentum in the US continues to be very strong in both pipelines and wins, including a new logo at a Fortune 500 company; most healthcare growth is coming from the US and Middle East/Australia, not UK NHS.
- Data and AI plays gaining traction: With BizAnalytica and data cloud modernization, the company is seeing strategic plays in Snowflake and Databricks, including wins that unify data platforms for Gen AI readiness.
Hiral Chandrana: "there is a good threshold of USD 100 million that we have crossed and that's now giving us confidence that, hey, we can aim for the next USD 100 million."
Account Strategy & Order Book
- Account mining shift paying off: An 18-month focus on account mining and strategic clients is showing progress, with clients moving from USD 1M to USD 5M and USD 5M to USD 10M bands, and a pipeline of sub-USD 1M accounts being built as future large accounts.
- Cross-sell traction: Within the top 30 accounts, more than one service line is present in about 15-16 of them, indicating deepening relationships.
- New logo quality over quantity: The company is now focused on clients above USD 1 billion, and in many cases USD 2 billion to USD 10 billion, deliberately raising the quality bar for new logos.
- Order book momentum: The 12-month backlog has consistently grown quarter-on-quarter over the last couple of quarters across all geographies, underpinning management's confidence despite macro uncertainty.
- Deal characteristics shifting to annuity: A public sector deal announced this quarter converts development and build work into managed services, delivering more annuity and sticky revenue.
- Large deal ambition with margin awareness: Management will start competing in larger deals and going after larger accounts, accepting that some may come at below-average margins in the short term as long as overall company-level profitability is maintained.
Hiral Chandrana: "We have been much more careful in terms of the new logos... we are mostly focused on now clients above USD 1 billion, in many cases USD 2 billion, USD 5 billion, USD 10 billion clients."
NHS Revival & UK Healthcare
- NHS stability emerging: A small uptick in business gives management confidence in stability over the coming quarters and years, though the tone remains cautious.
- Revival plan now in place: A new UK healthcare leader was onboarded two months ago, an outside agency has been hired for insights, and a complete plan for NHS revival and growth now covers multiple areas beyond the central NHS agency, including secondary care and arm's-length bodies.
- NHS growth expected in FY '25: Management expects NHS accounts to grow in FY '25, but remains cautious given the history.
- Higher education niche: While not a very large spend area, the company has interesting momentum with wins at Nottingham and the University of Durham.
Hiral Chandrana: "I wish we had done that earlier, frankly. And now we have a complete plan for NHS revival and growth paths where the team is plotting not just one area, but multiple areas beyond the central agency of NHS."
Geographic & Portfolio Reshaping
- Strategic geographic exits: The company has started to exit Malaysia, Singapore, and the India business, resulting in a slight attrition spike that management expects to stabilize and decline in future quarters.
- Middle East diversification: Wins in the Middle East now extend beyond Oracle Cloud into ServiceNow and Microsoft opportunities, with margins improving a little and visibility on further improvement.
- Middle East growth deliberately measured: Management believes the Middle East could grow much faster but is being very careful, choosing not to go after certain deals.
- Global manufacturing deal closed: A large global deal was closed at a INR 500 crore manufacturing company, taking a transformational approach to end-to-end processes including order-to-cash, procure-to-pay, and record-to-report.
- AWS and analyst recognition: AWS recognized Mastek as a top three upcoming partner, and TechMarketView identified Mastek in the UK as one of the suppliers on the rise.
Hiral Chandrana: "we have started to exit certain geographies like Malaysia, Singapore, and India business that has resulted in a little bit of attrition spike, but we believe that will stabilize and keep going down in the future quarters."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Margin range | Operate between 17-19% EBITDA; combination of Middle East and US margin improvement to bring overall profile to midpoint of that range | Steady state going forward |
| US margin improvement | Margin profile will continue to improve; more leverage definitely available | Ongoing |
| Headcount growth | As utilization improves and more customers are added, company will look to increase headcount | Coming quarters |
| NHS growth | NHS accounts will grow, but management remains cautious | FY '25 |
| Secure government growth | Central government and defense will continue to grow at company average rate | Q4 and beyond into FY '25 |
| Attrition stabilization | Attrition spike from geographic exits expected to stabilize and decline | Future quarters |
| Large deal participation | Will start competing in larger deals, accepting short-term margin dilution while maintaining overall company profitability | Ongoing |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue | ₹784 cr, up 2.4% QoQ and 19.1% YoY |
| Revenue growth (USD terms) | 17.4% YoY |
| Constant currency revenue growth | 2.7% QoQ and 13.4% YoY |
| Organic constant currency revenue growth | 0.7% QoQ |
| Operating EBITDA margin | 17.0%, up 90 bps QoQ |
| Profit after tax | ₹77.7 cr, up 19% QoQ and 15.8% YoY |
| 12-month order backlog | $248 million, up 11% QoQ and 21% YoY |
| Order book backlog growth | 21.2% YoY |
| Utilization (excluding leave) | 85.4%, up 130 bps QoQ |
| Closing headcount | 5,518, net reduction of 80 |
| New customers added | 27 during the quarter |
| Gross cash | ₹404 cr as of December 31, 2023 |
| Borrowing | ₹464 cr at end of December |
| Net debt | ₹60 cr at end of December 31 |
| Dividend declared | 140%, ₹7 per share |